下颌前移装置对重度阻塞性睡眠呼吸暂停患者内皮功能的影响
本研究将150例无显性心血管疾病的重度OSA患者随机分为有效下颌前移装置组与假装置组,治疗2个月。意向性分析显示,有效下颌前移装置未改善内皮功能(反应性充血指数)及血压,但显著改善呼吸暂停低通气指数、微觉醒指数及打鼾、乏力、嗜睡症状,且客观依从性高。
要点
- 有效下颌前移装置未改善重度OSA患者的内皮功能与血压。
- 该治疗显著降低AHI、微觉醒指数并改善打鼾、乏力与嗜睡症状。
- 客观依从性为有效装置6.6 h/night、假装置5.6 h/night(P=0.006)。
核心结论
- 在中等嗜睡的重度OSA患者中,下颌前移治疗降低OSA严重程度及相关症状,但尽管依从性高,对内皮功能和血压无影响。
研究设计与样本
- 随机对照试验,150例重度OSA且无显性心血管疾病患者随机接受有效下颌前移装置(n=75)或假装置(n=75)治疗2个月。
- 主要结局为反应性充血指数变化,按意向性治疗分析;嵌入式微传感器客观测量治疗依从性。
主要发现
- 意向性治疗分析中,有效下颌前移装置与假装置相比未改善内皮功能。
- 两组诊室及动态血压结局无差异。
- 有效下颌前移装置显著改善呼吸暂停低通气指数(P < 0.001)、微觉醒指数(P = 0.008)及打鼾、乏力、嗜睡症状(P < 0.001)。
- 平均(SD)客观依从性:有效装置6.6(1.4)h/night,假装置5.6(2.3)h/night(P = 0.006)。
关键数值与推荐
- 纳入患者86%为男性,平均(SD)年龄54(10)岁,呼吸暂停低通气指数中位数(四分位距)41(35-53),平均(SD)Epworth嗜睡量表9.3(4.2)。
临床怎么用
- 对中等嗜睡的重度OSA患者,下颌前移装置可改善OSA严重程度及症状,但不应期望其改善内皮功能或血压。
局限性
- 研究对象为无显性心血管疾病的中等嗜睡重度OSA患者,治疗时长2个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Endothelial dysfunction, a major predictor of late cardiovascular events, is linked to the severity of obstructive sleep apnea (OSA). OBJECTIVES: To determine whether treatment with mandibular advancement device, the main alternative to continuous positive airway pressure, improves endothelial function in patients with severe OSA. METHODS: In this trial, we randomized patients with severe OSA and no overt cardiovascular disease to receive 2 months of treatment with either effective mandibular advancement device or a sham device. The primary outcome, change in reactive hyperemia index, a validated measurement of endothelial function, was assessed on an intention-to-treat basis. An embedded microsensor objectively measured treatment compliance. MEASUREMENTS AND MAIN RESULTS: A total of 150 patients (86% males; mean [SD] age, 54 [10] yr; median [interquartile range] apnea-hypopnea index, 41 [35-53]; mean [SD] Epworth sleepiness scale, 9.3 [4.2]) were randomized to effective mandibular advancement device (n = 75) or sham device (n = 75). On intention-to-treat analysis, effective mandibular advancement device therapy was not associated with improvement of endothelial function compared with the sham device. Office and ambulatory blood pressure outcomes did not differ between the two groups. Effective mandibular advancement device therapy was associated with significant improvements in apnea-hypopnea index (P < 0.001); microarousal index (P = 0.008); and symptoms of snoring, fatigue, and sleepiness (P < 0.001). Mean (SD) objective compliance was 6.6 (1.4) h/night with the effective mandibular advancement device versus 5.6 (2.3) h/night with the sham device (P = 0.006). CONCLUSIONS: In moderately sleepy patients with severe OSA, mandibular advancement therapy reduced OSA severity and related symptoms but had no effect on endothelial function and blood pressure despite high treatment compliance. Clinical trial registered with www.clinicaltrials.gov (NCT 01426607).
引用
- Gagnadoux F, Pépin JL, Vielle B, et al. Impact of Mandibular Advancement Therapy on Endothelial Function in Severe Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2017. PMID: 28128967. doi:10.1164/rccm.201609-1817OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。